Who are Eprotirome and ezetimibe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Evrenzo, Unithroid, Choloxin, Triostat, T3 (Triiodothyronine), Levothyroxine Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eprotirome-and-ezetimibe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Eprotirome and ezetimibe — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eprotirome and ezetimibe (Eprotirome and ezetimibe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone receptor antagonist and cholesterol absorption inhibitor. Area: Cardiovascular.

phase 2 Thyroid hormone receptor antagonist and cholesterol absorption inhibitor Thyroid hormone receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Eprotirome and ezetimibe (Eprotirome and ezetimibe) — Karo Bio AB. Eprotirome is a thyroid hormone receptor antagonist, and ezetimibe is a cholesterol absorption inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eprotirome and ezetimibe TARGET	Eprotirome and ezetimibe	Karo Bio AB	phase 2	Thyroid hormone receptor antagonist and cholesterol absorption inhibitor	Thyroid hormone receptor
Evrenzo	ROXADUSTAT	Astellas Pharma Europe B.V.	marketed		Thyroid hormone receptor beta	2021-01-01
Unithroid	LEVOTHYROXINE SODIUM	Fresenius Kabi	marketed	l-Thyroxine	Thyroid hormone receptor beta	2000-01-01
Choloxin	DEXTROTHYROXINE	AbbVie	marketed	dextrothyroxine	Thyroid hormone receptor	1967-01-01
Triostat	LIOTHYRONINE	Pfizer	marketed	l-Triiodothyronine	Thyroid hormone receptor alpha	1956-01-01
T3 (Triiodothyronine)	T3 (Triiodothyronine)	National Institute of Mental Health (NIMH)	marketed	Thyroid hormone	Thyroid hormone receptor (TR-alpha, TR-beta)
Levothyroxine Tablet	Levothyroxine Tablet	University of California, Los Angeles	marketed	Thyroid hormone replacement	Thyroid hormone receptor (TR-alpha and TR-beta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone receptor antagonist and cholesterol absorption inhibitor class)

Karo Bio AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eprotirome and ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/eprotirome-and-ezetimibe. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab